Effect of protein kinase inhibitors on the growth, morphology, and infectivity of Leishmania promastigotes

被引:0
作者
S. Becker
C. L. Jaffe
机构
[1] Department of Parasitology,
[2] Kuvin Center for Tropical and Infectious Diseases,undefined
[3] Hebrew University-Hadassah Medical School,undefined
[4] P.O. Box 12272,undefined
[5] Jerusalem 91120,undefined
[6] Israel Tel.: 972-2-6758076; Fax: 972-2-6757425 e-mail: cjaffe@cc.huji.ac.il,undefined
来源
Parasitology Research | 1997年 / 83卷
关键词
Protein Kinase; Morphological Change; Minor Effect; Peritoneal Macrophage; Staurosporine;
D O I
暂无
中图分类号
学科分类号
摘要
The effect of two protein kinase inhibitors, staurosporine and H-7, on the growth, morphology and infectivity of Leishmania major and Leishmania amazonensis promastigotes was examined. Incubation with H-7 (600 μM) for up to one hour had no effect on parasite growth, morphology or infectivity. Staurosporine, however, was cytotoxic for promastigotes and incubation for 1, 5 or 15 minutes with 10 μM inhibitor killed 19, 34 and 59 %, respectively, of the parasites. Longer incubations, up to one hour, at this concentration did not increase parasite killing. However, treatment with 25 μM staurosporine for one hour was highly toxic, only 4 % of the promastigotes surviving after 72 h. Lower concentrations of staurosporine, 0.25 and 2.5 μM, had only minor effects on parasite growth. Incubation of either L. major or L. amazonensis with staurosporine (10 μM for 10 minutes) caused marked morphological changes in the size and appearance of the flagellar pocket, and/or cytoplasm of the viable parasites. Treated parasites were still capable of infecting mouse peritoneal macrophages and causing disease in BALB/c mice, though the treated parasites were less virulent than control promastigotes. These results indicate that staurosporine, while inhibiting promastigote growth, does not prevent differentiation to amastigotes and amastigote replication.
引用
收藏
页码:273 / 280
页数:7
相关论文
共 50 条
  • [21] Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin
    Kestav, Katrin
    Uri, Asko
    Lavogina, Darja
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (21) : 2276 - 2293
  • [22] Emerging protein kinase inhibitors for the treatment of multiple myeloma
    Lind, Judith
    Czernilofsky, Felix
    Vallet, Sonia
    Podar, Klaus
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (03) : 133 - 152
  • [23] Toward the rational design of protein kinase casein kinase-2 inhibitors
    Sarno, S
    Moro, S
    Meggio, F
    Zagotto, G
    Dal Ben, D
    Ghisellini, P
    Battistutta, R
    Zanotti, G
    Pinna, LA
    PHARMACOLOGY & THERAPEUTICS, 2002, 93 (2-3) : 159 - 168
  • [24] Protein kinase inhibitors: breakthrough medicines and the next generation
    Sawyer, Tomi K.
    Wu, Joe C.
    Sawyer, Jonathon R.
    English, Jessie M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 675 - 678
  • [25] Differentiating pulmonary hypertension associated with protein kinase inhibitors
    Jacobs, Joshua A.
    Jahangir, Eiman
    Ryan, John J.
    PULMONARY CIRCULATION, 2022, 12 (02)
  • [26] Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes
    Gschwendt, M
    Dieterich, S
    Rennecke, J
    Kittstein, W
    Mueller, HJ
    Johannes, FJ
    FEBS LETTERS, 1996, 392 (02): : 77 - 80
  • [27] Identification of Potential Kinase Inhibitors within the PI3K/AKT Pathway of Leishmania Species
    Ochoa, Rodrigo
    Ortega-Pajares, Amaya
    Castello, Florencia A.
    Serral, Federico
    Fernandez Do Porto, Dario
    Villa-Pulgarin, Janny A.
    Varela-M, Ruben E.
    Muskus, Carlos
    BIOMOLECULES, 2021, 11 (07)
  • [28] Editorial: Protein kinase inhibitors in neurodegeneration and cancer targeted therapies
    Anwar, Saleha
    Ahmed, Azaj
    Sarli, Vasiliki
    Hassan, Imtaiyaz
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [29] Recent developments of protein kinase inhibitors as potential AD therapeutics
    Tell, Volkmar
    Hilgeroth, Andreas
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2013, 7
  • [30] Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges
    Ling, Yuan
    Zhang, Zikang
    Zhang, Hua
    Huang, Zunnan
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (29) : 4303 - 4310